Initial AX-0810 data show no safety signals after 4 weeks of dosing and pharmacokinetics consistent with non-clinical data; ...
Ascidian Therapeutics ("Ascidian"), a biotechnology company seeking to treat human diseases by rewriting RNA, and Forge ...
New research led by Joshua Rosenthal, PhD, of the Marine Biological Laboratory (MBL) and Eli Eisenberg, PhD, at Tel Aviv University, has revealed that octopuses and their close relatives adjust to ...
Treating acute myeloid leukemia (AML) depends on knowing what goes wrong inside cells. A new study suggests that two genetic ...
Maddy has a degree in biochemistry from the University of York and specializes in reporting on health, medicine, and genetics. Maddy has a degree in biochemistry from the University of York and ...
Innovative research into the gene-editing tool targets influenza’s ability to replicate—stopping it in its tracks.
AZoLifeSciences on MSN
Synthetic RNA platform converts viral replication into detectable cellular signals
The technology, called the Viral-Engineered RNA-based Activation System (VERAS), hijacks the virus's own replication ...
In a paper published on aBIOTECH, the authors investigated the off-target effects of ADAR-mediated RNA editing in rice ...
The most recent developments in the field of A-to-I RNA modification, with a special emphasis on the roles of A-to-I in the genesis and progression of cancer. Adenosine-to-inosine (A-to-I) RNA editing ...
New research provides a mechanistic map of how genetic mutations disrupt RNA splicing in acute myeloid leukemia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback